Notably, it was anticipated that the keyword trends concerning “cancer immunotherapy,” “bispecific antibody,” “monoclonal antibody,” “multiple myeloma,” and “antibody-dependent enhancement” would persist into 2025, underscoring their enduring relevance as key subjects within the field of FcγR and indicating FcγR is beginning to be gradually applied to tumor immunotherapy, and its potential in this field is gradually being explored. Here, FCGR2A is linked to plasma cell myeloma.